In post-PCI management, which combination therapy is commonly prescribed to prevent recurrent myocardial infarction?

In post-PCI management, which combination therapy is commonly prescribed to prevent recurrent myocardial infarction?

• A. Anticoagulation with Warfarin Alone
• B. Calcium Channel Blocker Therapy
• C. Dual Antiplatelet Therapy (Aspirin Plus a P2Y12 Inhibitor)
• D. Statin Therapy Alone

Answer: (C)

After PCI, preventing platelet-driven thrombosis on the stent is essential to avoid a recurrent heart attack. The standard approach is dual antiplatelet therapy, combining aspirin with a P2Y12 receptor inhibitor. Aspirin blocks thromboxane A2 production, which reduces platelet activation, while the P2Y12 inhibitor (such as clopidogrel, prasugrel, or ticagrelor) prevents ADP-mediated platelet aggregation. This complementary action on two different pathways makes the therapy highly effective at lowering the risk of stent thrombosis and recurrent MI after PCI. Durations vary based on the type of stent and bleeding risk, but the principle remains: provide ongoing antiplatelet protection during the period of highest risk, with considerations for long-term aspirin continuation and individual bleeding risk. Other therapies like anticoagulation with warfarin alone, calcium channel blockers, or statins alone do not provide the same proven protection against recurrent MI immediately after PCI.

After PCI, preventing platelet-driven thrombosis on the stent is essential to avoid a recurrent heart attack. The standard approach is dual antiplatelet therapy, combining aspirin with a P2Y12 receptor inhibitor. Aspirin blocks thromboxane A2 production, which reduces platelet activation, while the P2Y12 inhibitor (such as clopidogrel, prasugrel, or ticagrelor) prevents ADP-mediated platelet aggregation. This complementary action on two different pathways makes the therapy highly effective at lowering the risk of stent thrombosis and recurrent MI after PCI.

Durations vary based on the type of stent and bleeding risk, but the principle remains: provide ongoing antiplatelet protection during the period of highest risk, with considerations for long-term aspirin continuation and individual bleeding risk. Other therapies like anticoagulation with warfarin alone, calcium channel blockers, or statins alone do not provide the same proven protection against recurrent MI immediately after PCI.